Quarterly report · Q1
2160.TEDINET S100TFYV
Period2024-01-01 → 2024-03-31
Filed2024-05-15
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥5.9bn | 2024-01-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥26.0bn | 2023-01-01 → 2023-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥4.2bn | 2023-01-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Operating income | ¥2.3bn | 2024-01-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥398m | 2023-01-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥1.8bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥12.6bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥65m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥1.5bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥8.1bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥3m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥1.3bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥9.5bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | −¥342m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥65.6bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥62.4bn | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥34.1bn | at 2023-03-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥27.8bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥26.3bn | at 2023-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥37.8bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥36.1bn | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.8bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.8bn | at 2022-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥34.6bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥33.8bn | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥21.2bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥20.3bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥21.6bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥10.6bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.0bn | at 2022-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | −¥350m | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥6.5bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥710m | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥1.8bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥6.8bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥1.2bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥88m | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥10.7bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥52m | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥29.17 | 2024-01-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥169.5 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-0.06 | 2023-01-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥28 | 2024-01-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥165.56 | 2023-01-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-0.06 | 2023-01-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 52.7% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 54.2% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 62.2% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 22
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥1.3bn |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥1.3bn |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥539m |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥4.6bn |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥4.6bn |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥1.7bn |
| —segment total | revenue | 2024-01-01 → 2024-03-31 | ¥5.9bn |
| —segment total | revenue external | 2024-01-01 → 2024-03-31 | ¥5.9bn |
| —segment total | segment profit | 2024-01-01 → 2024-03-31 | ¥2.3bn |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-03-31 | −¥23m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-03-31 | −¥23m |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥623m |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥600m |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥23m |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥248m |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥3.6bn |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥3.6bn |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥149m |
| —segment total | revenue | 2023-01-01 → 2023-03-31 | ¥4.2bn |
| —segment total | revenue external | 2023-01-01 → 2023-03-31 | ¥4.2bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥23m |
| —segment total | segment profit | 2023-01-01 → 2023-03-31 | ¥398m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 599
| Item | Context | Value | Unit |
|---|---|---|---|
| Equity IFRS | CurrentQuarterInstant | 37754200000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | -64934000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | 1827172000 | JPY |
| Depreciation expense ope cf IFRS | Prior1YTDDuration | 136501000 | JPY |
| Depreciation expense ope cf IFRS | CurrentYTDDuration | 199906000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | Prior1YTDDuration | 634319000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | CurrentYTDDuration | -260411000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | Prior1YTDDuration | -355840000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | CurrentYTDDuration | 47887000 | JPY |
| Decrease increase in inventories ope cf IFRS | Prior1YTDDuration | 14720000 | JPY |
| Decrease increase in inventories ope cf IFRS | CurrentYTDDuration | -31039000 | JPY |
| Bonus allowance ope cf IFRS | Prior1YTDDuration | 6167000 | JPY |
| Bonus allowance ope cf IFRS | CurrentYTDDuration | -84495000 | JPY |
| Finance income and finance costs ope cf IFRS | Prior1YTDDuration | 190440000 | JPY |
| Finance income and finance costs ope cf IFRS | CurrentYTDDuration | 173920000 | JPY |
| Loss gain on valuation in securities ope cf IFRS | Prior1YTDDuration | 45691000 | JPY |
| Loss gain on valuation in securities ope cf IFRS | CurrentYTDDuration | -124014000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1YTDDuration | 374706000 | JPY |
| Other changes in working capital ope cf IFRS | CurrentYTDDuration | -1408962000 | JPY |
| Subtotal ope cf IFRS | Prior1YTDDuration | 981771000 | JPY |
| Subtotal ope cf IFRS | CurrentYTDDuration | 339964000 | JPY |
| Interest received ope cf IFRS | Prior1YTDDuration | 22066000 | JPY |
| Interest received ope cf IFRS | CurrentYTDDuration | 86115000 | JPY |
| Interest paid ope cf IFRS | Prior1YTDDuration | -5516000 | JPY |
| Interest paid ope cf IFRS | CurrentYTDDuration | -19094000 | JPY |
| Income taxes refund paid ope cf IFRS | Prior1YTDDuration | -288361000 | JPY |
| Income taxes refund paid ope cf IFRS | CurrentYTDDuration | -757237000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YTDDuration | 709959000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYTDDuration | -350252000 | JPY |
| Net decrease increase in time deposits inv cf IFRS | Prior1YTDDuration | -771072000 | JPY |
| Net decrease increase in time deposits inv cf IFRS | CurrentYTDDuration | 539282000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | Prior1YTDDuration | -267660000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | CurrentYTDDuration | -150843000 | JPY |
| Purchase of intangible assets inv cf IFRS | Prior1YTDDuration | -198631000 | JPY |
| Purchase of intangible assets inv cf IFRS | CurrentYTDDuration | -149905000 | JPY |
| Increase of leasehold and guarantee deposits inv cf IFRS | Prior1YTDDuration | -3599000 | JPY |
| Increase of leasehold and guarantee deposits inv cf IFRS | CurrentYTDDuration | -2039620000 | JPY |
| Collection of loans receivable inv cf IFRS | Prior1YTDDuration | 1185000 | JPY |
| Collection of loans receivable inv cf IFRS | CurrentYTDDuration | － | JPY |
| Net cash provided by used in investing activities IFRS | Prior1YTDDuration | -1239778000 | JPY |
| Net cash provided by used in investing activities IFRS | CurrentYTDDuration | -1801086000 | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | Prior1YTDDuration | － | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | CurrentYTDDuration | 2687000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1YTDDuration | － | JPY |
| Repayments of long term borrowings fin cf IFRS | CurrentYTDDuration | -100000000 | JPY |
| Capital contribution from non controlling interests fin cf IFRS | Prior1YTDDuration | － | JPY |
| Capital contribution from non controlling interests fin cf IFRS | CurrentYTDDuration | 520205000 | JPY |
| Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRS | Prior1YTDDuration | － | JPY |
| Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRS | CurrentYTDDuration | -3269100000 | JPY |
| Proceeds from exercise of share acquisition rights fin cf IFRS | Prior1YTDDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |